Univest
Univest
  • Markets

Top 3 Pharma Stocks to Watch in 2027: Divi’s Labs, Mankind Pharma and Aurobindo Pharma

  • November 19, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Top 3 Pharma Stocks to Watch in 2027: Divi's Labs, Mankind Pharma and Aurobindo Pharma

Divi’s Labs Rs 11,049.00, Q2 PAT +63.6%. Mankind Pharma Rs 2,625.00, Q2 PAT +37.7%. Aurobindo Pharma Rs 1,796.30, Q2 PAT +32.5%. Prices as of 18 Nov 2026.

Quick Answer

The pharma stocks to watch in 2027 are Divi’s Laboratories, Mankind Pharma and Aurobindo Pharma, based on their latest results, returns and balance sheets. Divi’s Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The best figures in the group are 63.6% quarterly profit growth, a PE of 25.99 and a return on equity of 18.69%. Each stock has its own risks, so investors should match the choice to their holding period and risk appetite.

The pharma stocks to watch in 2027 are best picked on reported numbers. US generic launches, contract manufacturing for global drug makers and steady domestic demand are driving Indian pharma, and the three companies on this list grew September 2026 quarter profit by more than 32%.

This list covers Divi’s Laboratories, Mankind Pharma and Aurobindo Pharma. Each company is assessed on quarterly and annual profit growth, return on equity, debt, valuation and where its share price sits in its 52-week range. Prices are as of the 18 November 2026 close.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Top 3 Pharma Stocks to Watch in 2027 at a Glance
  • Why Are These the Pharma Stocks to Watch in 2027?
  • What Could Drive Pharma Stocks in 2027?
  • 1. Divi’s Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet
    • Divi’s Labs Financial Performance
    • What to Watch in Divi’s Labs for 2027
  • 2. Mankind Pharma: Domestic Branded Medicines Leader
    • Mankind Pharma Financial Performance
    • What to Watch in Mankind Pharma for 2027
  • 3. Aurobindo Pharma: US Generics Leader at the Lowest PE
    • Aurobindo Pharma Financial Performance
    • What to Watch in Aurobindo Pharma for 2027
  • How Do Divi’s Labs, Mankind Pharma and Aurobindo Pharma Compare?
  • Key Risks for Pharma Stocks in 2027
  • Conclusion
  • Frequently Asked Questions on Pharma Stocks to Watch in 2027
    • Which are the best pharma stocks to watch in 2027?
    • Which pharma stock has grown profit the fastest?
    • Which of these pharma stocks is the most attractively valued?
    • Which pharma stock has the lowest valuation?
    • What are the key risks for pharma stocks in 2027?
    • Should I invest in pharma stocks for the long term?

Top 3 Pharma Stocks to Watch in 2027 at a Glance

Divi’s Labs, Mankind Pharma and Aurobindo Pharma have a combined market capitalisation of about Rs 5.07 lakh crore. The table below compares these pharma stocks to watch in 2027 on the metrics that matter most for long-term investors.

Metric Divi’s Labs Mankind Pharma Aurobindo Pharma
Company Divi’s Laboratories Mankind Pharma Aurobindo Pharma
NSE Symbol DIVISLAB MANKIND AUROPHARMA
Share Price (Rs) 11,049.00 2,625.00 1,796.30
52-Week Closing High (Rs) 11,565.50 2,668.30 1,855.30
52-Week Closing Low (Rs) 5,821.00 1,927.40 1,121.70
Market Cap (Rs Cr) 2,93,874 1,09,040 1,03,626
PE Ratio 87.39 48.17 25.99
ROE 18.69% 12.76% 10.13%
Debt to Equity 0.00 0.31 0.22
Dividend Yield 0.27% 0.04% 0.22%

On valuation, the stocks trade at the following PE ratios: Divi’s Labs at 87.39 against an industry PE of 40.12; Mankind Pharma at 48.17 against an industry PE of 40.12; Aurobindo Pharma at 25.99 against an industry PE of 40.12. Aurobindo Pharma trades below the industry multiple, while Divi’s Labs and Mankind Pharma carry a premium that the market usually pays for faster growth or stronger returns.

Why Are These the Pharma Stocks to Watch in 2027?

These three made the list of pharma stocks to watch in 2027 because of earnings delivery and balance sheet quality. Indian pharma companies earn money in three main ways: selling branded medicines in India, exporting generic drugs to the US and Europe, and manufacturing ingredients or drugs for global pharma companies under contract. The three stocks on this list each lead one of these models.

In the September 2026 quarter, net profit grew 63.6% at Divi’s Labs, 37.7% at Mankind Pharma and 32.5% at Aurobindo Pharma. Return on equity ranges from 10.13% to 18.69%, which shows how efficiently each company uses shareholder capital. Divi’s Labs runs with little or no debt.

What Could Drive Pharma Stocks in 2027?

Pharma stocks in 2027 will be driven by new US generic approvals, pricing pressure in the US generics market, growth in chronic therapies in India, and contract manufacturing orders as global drug makers diversify their supply chains.

US FDA inspection outcomes are a key risk to track, since a warning letter can delay approvals from a plant. Divi’s Laboratories and Aurobindo Pharma are constituents of the Nifty Pharma, so their results move the sector index.

1. Divi’s Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet

Divi’s Laboratories makes active pharmaceutical ingredients and custom-synthesised molecules for global pharma companies, and it is one of the world’s largest makers of several generic APIs.

Divi’s Labs Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 3,770 2,860 +31.8%
Net Profit (Rs Cr) 1,127 689 +63.6%
Revenue FY26 vs FY25 (Rs Cr) 11,067 9,712 +14.0%
Net Profit FY26 vs FY25 (Rs Cr) 2,568 2,191 +17.2%

For FY26, revenue came in at Rs 11,067 crore (+14.0%), and net profit rose 17.2% to Rs 2,568 crore.

What to Watch in Divi’s Labs for 2027

Divi’s Labs grew September 2026 quarter net profit 63.6% to Rs 1,127 crore on 31.8% higher revenue, the fastest in this group, and it has the highest ROE at 18.69% with no debt. Its PE of 87.39 is far above the industry PE of 40.12, so investors should be careful about valuation and track new custom synthesis contracts. The stock closed at Rs 11,049.00 on 18 November 2026, about 4.5% below its 52-week closing high of Rs 11,565.50 and 89.8% above its 52-week closing low of Rs 5,821.00.

2. Mankind Pharma: Domestic Branded Medicines Leader

Mankind Pharma is one of India’s largest domestic pharma companies by sales volume, known for brands such as Manforce, Prega News and Gas-O-Fast, with a strong presence in smaller towns.

Mankind Pharma Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 4,432.71 3,789.03 +17.0%
Net Profit (Rs Cr) 716.12 520.18 +37.7%
Revenue FY26 vs FY25 (Rs Cr) 14,636.43 12,744.23 +14.8%
Net Profit FY26 vs FY25 (Rs Cr) 1,938.10 2,006.59 Lower YoY

For FY26, revenue came in at Rs 14,636.43 crore (+14.8%), and net profit stood at Rs 1,938.10 crore. Net profit has compounded at about 7.5% a year from FY22 to FY26.

What to Watch in Mankind Pharma for 2027

Mankind Pharma grew September 2026 quarter net profit 37.7% to Rs 716.12 crore on 17.0% higher revenue. Investors should track the integration of its Bharat Serums and Vaccines acquisition, which added women’s health and critical care products. The stock closed at Rs 2,625.00 on 18 November 2026, about 1.6% below its 52-week closing high of Rs 2,668.30 and 36.2% above its 52-week closing low of Rs 1,927.40.

Compare Pharma Stocks on the Univest Screener

3. Aurobindo Pharma: US Generics Leader at the Lowest PE

Aurobindo Pharma is one of the largest Indian exporters of generic medicines to the US and Europe, with a wide portfolio of oral, injectable and biosimilar products.

Aurobindo Pharma Financial Performance

Metric Latest Year Earlier Change
Revenue (Rs Cr) 10,431.51 8,406.29 +24.1%
Net Profit (Rs Cr) 1,123.84 848.13 +32.5%
Revenue FY26 vs FY25 (Rs Cr) 34,145.17 32,345.58 +5.6%
Net Profit FY26 vs FY25 (Rs Cr) 3,502.97 3,483.57 +0.6%

For FY26, revenue came in at Rs 34,145.17 crore (+5.6%), and net profit rose 0.6% to Rs 3,502.97 crore. Net profit has compounded at about 7.3% a year from FY22 to FY26.

What to Watch in Aurobindo Pharma for 2027

Aurobindo Pharma grew September 2026 quarter net profit 32.5% to Rs 1,123.84 crore and revenue 24.1% to Rs 10,431.51 crore. It trades at a PE of 25.99, the lowest of the three and below the industry PE of 40.12. Investors should track US FDA inspection outcomes and its biosimilars pipeline. The stock closed at Rs 1,796.30 on 18 November 2026, about 3.2% below its 52-week closing high of Rs 1,855.30 and 60.1% above its 52-week closing low of Rs 1,121.70.

How Do Divi’s Labs, Mankind Pharma and Aurobindo Pharma Compare?

The table below puts quarterly growth, annual profit, valuation and price position for the three pharma stocks side by side.

Metric Divi’s Labs Mankind Pharma Aurobindo Pharma
Q2 Net Profit Growth +63.6% +37.7% +32.5%
Latest Annual Net Profit (Rs Cr) 2,568 1,938.10 3,502.97
PE vs Industry PE 87.39 vs 40.12 48.17 vs 40.12 25.99 vs 40.12
Distance from 52-Week Closing High 4.5% below 1.6% below 3.2% below

For investors building a list of pharma stocks to watch in 2027, the right pick depends on priorities. Those who want growth momentum and capital efficiency may track Divi’s Labs and investors who want valuation comfort may prefer Aurobindo Pharma. Mankind Pharma gives exposure to a different part of the sector.

Key Risks for Pharma Stocks in 2027

Even the strongest pharma stocks to watch in 2027 carry risks that investors should weigh before buying.

US pricing pressure: Price erosion in US generics can reduce margins even when volumes grow.

Regulatory action: US FDA warning letters or import alerts can stop shipments from a plant.

Currency moves: A stronger rupee reduces the value of export revenue.

Valuation: Divi’s Labs and Mankind Pharma trade above the industry PE, so a slowdown in growth can lead to price corrections. Staggered buying helps manage entry risk.

Download the Univest iOS App or Univest Android App to track Divi’s Labs, Mankind Pharma and Aurobindo Pharma live and get daily stock research.

Conclusion

Divi’s Laboratories, Mankind Pharma and Aurobindo Pharma stand out among pharma stocks to watch in 2027 on growth, returns and balance sheet strength. Before investing, compare each stock’s PE with its profit growth, check where it trades in its 52-week range, and track the December and March quarter results to confirm the trend into 2027. Building positions gradually suits a sector where earnings can swing with US pricing pressure.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Pharma Stocks to Watch in 2027

Which are the best pharma stocks to watch in 2027?

Ans. Divi’s Laboratories, Mankind Pharma and Aurobindo Pharma are three of the strongest pharma stocks to watch in 2027 based on reported numbers. Divi’s Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The strongest figures in the group are 63.6% quarterly profit growth, a 18.69% return on equity and a PE of 25.99. Each company covers a different part of the pharma space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.

Which pharma stock has grown profit the fastest?

Ans. Divi’s Laboratories has grown profit the fastest among these three, with September 2026 quarter net profit up 63.6% year on year to Rs 1,127 crore. Mankind Pharma follows with 37.7% growth. Divi’s Labs’s latest annual net profit stood at Rs 2,568 crore for FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.

Which of these pharma stocks is the most attractively valued?

Ans. Aurobindo Pharma is the most attractively valued of the three, with a PE of 25.99 against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi’s Labs at 87.39. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.

Which pharma stock has the lowest valuation?

Ans. Aurobindo Pharma has the lowest valuation of the three with a PE of 25.99, against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi’s Laboratories at 87.39. Aurobindo’s lower PE reflects its exposure to the price-competitive US generics market, while Divi’s commands a premium for its contract manufacturing model and debt-free balance sheet. Investors should compare profit growth and return on equity along with the PE before deciding, since Divi’s also grew quarterly profit the fastest at 63.6%.

What are the key risks for pharma stocks in 2027?

Ans. The main risks for pharma stocks in 2027 are US pricing pressure, regulatory action and currency moves. Price erosion in US generics can reduce margins even when volumes grow. Valuation is another risk, since Divi’s Labs and Mankind Pharma trade above the industry PE. US FDA warning letters or import alerts can stop shipments from a plant. A stronger rupee reduces the value of export revenue. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.

Should I invest in pharma stocks for the long term?

Ans. Pharma stocks can suit long-term investors who understand the sector’s cycles and are comfortable with price swings. Divi’s Labs, Mankind Pharma and Aurobindo Pharma have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Divi’s Labs earns a 18.69% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.



Aurobindo Pharma divis laboratories Mankind Pharma Pharma Stocks pharmaceutical stocks
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply